About Innocoll

Innocoll is a specialty pharmaceutical company committed to improving the status quo and finding answers to unmet needs

About Us

XARACOLL® (bupivacaine HCl) Implant

Our lead product, XARACOLL, was approved by the U.S. Food and Drug Administration in August 2020

XARACOLL

Latest News

Anthony Galdi Appointed Chief Commercial Officer of Innocoll

10 Feb
ATHLONE, Ireland – Feb. 4, 2021 – Innocoll Holdings Limited, a specialty pharmaceutical company and portfolio business of Gurnet Point...
Read More

Louis Pascarella Appointed Chief Executive Officer of Innocoll

12 Jan
Louis Pascarella has been named the company’s Chief Executive Officer and a member of Innocoll’s Board of Directors. Pascarella, who will retain his current role of President, succeeds Rich Fante, who is stepping down after a successful tenure as CEO and has agreed to serve as an adviser to Innocoll’s Board for at least the next year to ensure a smooth transition.
Read More

Innocoll Announces Commercial Launch of XARACOLL® (bupivacaine HCI) implant, a Non-opioid, Drug-device Treatment Option for Acute Postsurgical Pain Relief for up to 24 Hours Following Open Inguinal Hernia Repair in Adults

29 Oct
First-in-class, fully bioresorbable, collagen implant delivers postsurgical pain relief directly to the surgical site ATHLONE, Ireland, Oct. 29, 2020 /PRNewswire/ -- Innocoll Holdings Limited,...
Read More

Business Development Group
Unit 9, Block D
Monksland Business Park
Monksland
Athlone
Co. Roscommon
Ireland

Phone: +353 (0)90 648 6834
Fax: +353 (0)90 648 6835
E-mail: inquiries@innocoll.com

Innocoll Holdings Limited, a private company limited by shares, incorporated in Ireland having company number 544604 and its registered office at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland.

© 2020-2004 Innocoll. All rights reserved.
All Trademarks are owned by Innocoll Pharmaceuticals Limited